Pharma Company Bags New Rs 44 Crore Order From United Nations International Children's Emergency Fund (UNICEF)
The company has a market cap of over Rs 3,000 crore and the stock gave multibagger returns of 382 per cent from its 52-week low of Rs 112.35 per share.
Panacea Biotec Ltd has secured an additional contract from the United Nations International Children's Emergency Fund (UNICEF), an international entity, for the supply of 40 million doses (2 million vials) of its bivalent oral polio vaccine (bOPV). This significant order, valued at approximately USD 5.20 million (around Rs 44 Crore), is slated for execution in the third quarter of calendar year 2025 and will necessitate an amendment to the existing Long-Term Arrangement between UNICEF and the Company. UNICEF will publicly disclose details of this award, including Panacea Biotec's name, the vaccine type, the duration of the award, the total value, and the awarded prices, on its official website.
Earlier, the company received a letter of award from UNICEF for the supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth USD 14.95 million (Rs 127 crore) in CY2025.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, download the service details here.
Established in 1984, Panacea Biotec Ltd stands as a research-driven biotechnology company deeply involved in the research, development, manufacturing, and marketing of a diverse portfolio encompassing branded vaccines, pharmaceutical formulations, nutraceuticals, and food & nutrition products. Notably, Panacea Biotec has emerged as one of India's leading vaccine manufacturers and has garnered recognition from the United Nations (UN) Health Agencies for its significant contributions to the Global Polio Eradication Initiative (GPEI), having supplied billions of doses of WHO-prequalified polio vaccines to over 50 countries following its comprehensive range of oral polio vaccines.
The company has a market cap of over Rs 3,000 crore and the stock gave multibagger returns of 382 per cent from its 52-week low of Rs 112.35 per share. Investors should keep an eye on this small-cap pharma stock.
Disclaimer: The article is for informational purposes only and not investment advice.